F-star’s goal is to offer cancer patients greater and more durable benefits than current immuno-oncology treatments
F-star generates first- and best-in-class drug candidates that seek to block tumour immune evasion mechanisms
F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies with the goal of creating a paradigm-shift in cancer therapy.
Immuno-oncology leverages the body’s natural immune response to fight cancer and is currently one the most exciting areas of research within the biopharmaceutical industry with several key drugs on the market and many in late-stage clinical development.
An Fcab is derived from the constant (Fc) region of an antibody - the "stem" of an antibody. Natural antibodies bind antigens via the variable (Fab) regions - the "arms" of an antibody. Our platform introduces new antigen binding sites into the Fc region.
F-star’s leadership team has decades of combined experience from holding senior-level positions in both pharma and biotech and involving the development of dozens of biologics from target selection to clinical trials.